TOPIVERT
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a Phase IIa proof of concept study in ulcerative colitis. A Phase I/II study with TOP1630 for dry eye syndrome will commence in the US in early 2017.
TOPIVERT
Industry:
Angel Investment Biotechnology Health Care Management Information Systems
Founded:
2011-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.topivert.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
19.9 M USD
Technology used in webpage:
Google Analytics Google Universal Analytics GoDaddy DNS ASP.NET IIS Pound Sterling IIS 8 Parallels Plesk Panel Plesk Classic ASP
Current Advisors List
Current Employees Featured
Founder
Investors List
SV Health Investors
SV Health Investors investment in Series A - TopiVert
Neomed Management
Neomed Management investment in Venture Round - TopiVert
Imperial Innovations
Imperial Innovations investment in Venture Round - TopiVert
SV Health Investors
SV Health Investors investment in Venture Round - TopiVert
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation investment in Venture Round - TopiVert
Imperial Innovations
Imperial Innovations investment in Venture Round - TopiVert
SV Health Investors
SV Health Investors investment in Venture Round - TopiVert
Official Site Inspections
http://www.topivert.com Semrush global rank: 5.39 M Semrush visits lastest month: 1.56 K
- Host name: ec2-3-130-253-23.us-east-2.compute.amazonaws.com
- IP address: 3.130.253.23
- Location: Columbus United States
- Latitude: 39.9653
- Longitude: -83.0235
- Metro Code: 535
- Timezone: America/New_York
- Postal: 43215
More informations about "TopiVert"
Topivert Pharma Limited Management Team | Org Chart
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic …See details»
Topivert Company Profile | Management and Employees List
TopiVert also expects to start the clinical development of TOP1630, its candidate for dry eye syndrome (DES), in early 2017. Current therapies for these debilitating diseases provide …See details»
TopiVert Company Profile 2024: Valuation, Funding & Investors
TopiVert General Information Description. Developer of medical inhibition technologies designed to treat chronic inflammatory diseases of the gastrointestinal tract and the eyes. The …See details»
Topivert Pharma Limited - Company Profile & Staff Directory
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic …See details»
Topivert Pharma Limited: Contact Details and Business Profile
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic …See details»
TopiVert Company Profile - Office Locations, Competitors ... - Craft
TopiVert has adopted a semi-virtual business model, using a combination of in-house expertise and a strong network of advisers and service providers to expedite our programmes and …See details»
TopiVert - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead ... obfuscated — Jan 12, 2014: Venture …See details»
TopiVert - VentureRadar
Topivert Ltd is a spin out company focussing on the development of small molecule drugs to treat severe inflammation of the gastrointestinal (GI) tract and eye. The company is based in the …See details»
Topivert - Company Profile - Tracxn
Oct 23, 2024 TopiVert is a clinical-stage company focussed on developing narrow spectrum kinase inhibitors for the treatment of chronic inflammatory diseases of the gastrointestinal tract …See details»
TopiVert - Products, Competitors, Financials, Employees, …
TopiVert will enter into an exclusive drug discovery collaboration with RespiVert aimed at identifying new NSKIs. TopiVert will receive exclusive rights to select and develop resulting …See details»
TOPIVERT PHARMA LIMITED - Companies House
More for TOPIVERT PHARMA LIMITED (07757916) Registered office address 1 More London Place, London, SE1 2AF . Company status Liquidation Company type Private limited …See details»
Topivert Pharma Ltd. - Drug pipelines, Patents, Clinical trials
Explore Topivert Pharma Ltd. with its drug pipeline, therapeutic area, technology platform, 8 clinical trials, 1 news, and 3 literature, Disease Domain:Endocrinology and Metabolic Disease, …See details»
TopiVert Ltd.:Company Profile & Technical Research,Competitor …
TopiVert is headquartered in United Kingdom England. TopiVert was founded in 2011. Related Topics. Angel investor Management information systems Medicine Health care …See details»
TopiVert - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Organization. TopiVert . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Total Products Active 8. Active Tech Count 2. …See details»
TopiVert receives IND approval for TOP1630 in the treatment of …
Nov 28, 2016 TopiVert also expects to start the clinical development of TOP1630, its candidate for dry eye syndrome (DES), in early 2017. Current therapies for these debilitating diseases …See details»
TopiVert | Biotechnology - The Pharmaletter
TopiVert A private, clinical-stage biotechnology company developing medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The company's …See details»
TopiVert - Contacts, Employees, Board Members, Advisors & Alumni
Organization. TopiVert . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... TopiVert has 2 current employee profiles, including …See details»
TOP-1288 - Drug Targets, Indications, Patents - Synapse - Patsnap
Topivert Pharma Ltd. EUCTR2016-000390-20-CZ / Not yet recruiting Phase 2 A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety/Tolerability and …See details»
TOP-1257 - Drug Targets, Indications, Patents - Synapse - Patsnap
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.See details»